Meta-regression Analysis of the Efficacy of Alendronate for Prevention of Glucocorticoid-induced Fractures

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2020 Oct 21

PMID 33080717

Authors

Mei Qiu

Liangliang Ding

Miao Zhang

Jinhao Lin

Hua Huang

Kaikai Li

Affiliations

Soon will be listed here.

Abstract

Background: What affects the efficacy of alendronate for prevention of glucocorticoid-induced (GI) fractures remains unclear. We aimed to explore the factors affecting alendronate's efficacy, and further identify subgroup effects of alendronate in preventing GI fractures.

Methods: We searched 3 databases. Random-effects meta-analysis was conducted to synthesize risk ratio (RR) and 95% confidence interval (CI) for each endpoint. Meta-regression analysis was used to explore sources of heterogeneity, and subgroup analysis was used to address heterogeneity and evaluate subgroup effects. We detected publication bias using funnel plots and Egger tests.

Results: We included 13 papers from 12 unique studies involving 46431 participants. Glucocorticoid (GC) dosage (P = .053) and proportion of previous vertebral fracture (PVF) (P = .047) were probably 2 sources of heterogeneity in meta-analysis for vertebral fractures, while GC duration (P = .020) was probably 1 for nonvertebral fractures. Alendronate reduced vertebral fractures in the high dosage subgroup (RR 0.61, 95% CI 0.44-0.86), but didn't in the low dosage subgroup (RR 1.56, 95% CI 0.20-12.02). Alendronate reduced vertebral fractures (RR 0.53, 95% CI 0.40-0.68) in the subgroup of PVF proportion <5%, but didn't (RR 0.76, 95% CI 0.42-1.37) in the subgroup of this proportion ≥5%. Alendronate reduced nonvertebral and hip fractures, whether in primary or in secondary prevention subgroup.

Conclusions: The findings in our study support that alendronate is used for the primary and secondary prevention of GI fractures, but do not support that alendronate is recommended as a first-line agent for patients receiving a low dose of GCs or patients with PVF.

References

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V . Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008; (1):CD001155. DOI: 10.1002/14651858.CD001155.pub2. View

Allen C, Yeung J, Vandermeer B, Homik J . Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev. 2016; 10:CD001347. PMC: 6461188. DOI: 10.1002/14651858.CD001347.pub2. View

Kendler D, Marin F, Zerbini C, Russo L, Greenspan S, Zikan V . Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2017; 391(10117):230-240. DOI: 10.1016/S0140-6736(17)32137-2. View

Bischoff-Ferrari H, Bhasin S, Manson J . Preventing Fractures and Falls: A Limited Role for Calcium and Vitamin D Supplements?. JAMA. 2018; 319(15):1552-1553. DOI: 10.1001/jama.2018.4023. View

Egger M, Davey Smith G, Schneider M, Minder C . Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-34. PMC: 2127453. DOI: 10.1136/bmj.315.7109.629. View

Qaseem A, Forciea M, Denberg T, Barry M, Cooke M, Fitterman N . Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians. Ann Intern Med. 2017; 166(11):818-839. DOI: 10.7326/M15-1361. View

Weinstein R . Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin North Am. 2012; 41(3):595-611. PMC: 3417039. DOI: 10.1016/j.ecl.2012.04.004. View

Bergman J, Nordstrom A, Nordstrom P . Alendronate Use and the Risk of Nonvertebral Fracture During Glucocorticoid Therapy: A Retrospective Cohort Study. J Clin Endocrinol Metab. 2017; 103(1):306-313. DOI: 10.1210/jc.2017-01912. View

10.

Buckley L, Humphrey M . Glucocorticoid-Induced Osteoporosis. N Engl J Med. 2018; 379(26):2547-2556. DOI: 10.1056/NEJMcp1800214. View

11.

van Staa T, Leufkens H, Abenhaim L, Zhang B, Cooper C . Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000; 15(6):993-1000. DOI: 10.1359/jbmr.2000.15.6.993. View

12.

Amiche M, Albaum J, Tadrous M, Pechlivanoglou P, Levesque L, Adachi J . Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials. Osteoporos Int. 2015; 27(5):1709-18. DOI: 10.1007/s00198-015-3455-9. View

13.

Kan S, Yuan Z, Li Y, Ai J, Xu H, Sun J . Alendronate prevents glucocorticoid-induced osteoporosis in patients with rheumatic diseases: A meta-analysis. Medicine (Baltimore). 2016; 95(25):e3990. PMC: 4998340. DOI: 10.1097/MD.0000000000003990. View

14.

Saag K, Petersen J, Brandi M, Karaplis A, Lorentzon M, Thomas T . Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med. 2017; 377(15):1417-1427. DOI: 10.1056/NEJMoa1708322. View

15.

Stoch S, Saag K, Greenwald M, Sebba A, Cohen S, Verbruggen N . Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J Rheumatol. 2009; 36(8):1705-14. DOI: 10.3899/jrheum.081207. View

16.

Adachi J, Saag K, Delmas P, Liberman U, Emkey R, Seeman E . Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001; 44(1):202-11. DOI: 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W. View

17.

Tanaka Y, Mori H, Aoki T, Atsumi T, Kawahito Y, Nakayama H . Analysis of bone metabolism during early stage and clinical benefits of early intervention with alendronate in patients with systemic rheumatic diseases treated with high-dose glucocorticoid: Early DIagnosis and Treatment of OsteopoRosis in Japan.... J Bone Miner Metab. 2015; 34(6):646-654. DOI: 10.1007/s00774-015-0709-8. View

18.

Homik J, Suarez-Almazor M, Shea B, Cranney A, Wells G, Tugwell P . Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev. 2000; (2):CD000952. PMC: 7046131. DOI: 10.1002/14651858.CD000952. View

19.

Sambrook P, Kotowicz M, Nash P, Styles C, Naganathan V, Henderson-Briffa K . Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res. 2003; 18(5):919-24. DOI: 10.1359/jbmr.2003.18.5.919. View

20.

Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V . Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008; (1):CD004523. DOI: 10.1002/14651858.CD004523.pub3. View